Company Overview and News

1
Fitbit announces new Care platform for health plans, expands Humana partnership

13h marketwatch
Fitbit Inc. on Wednesday announced its new Fitbit Care platform, part of the company’s broader efforts to entice more health-care players and generate recurring revenue.
FIT HUM

20
Cigna deal gets antitrust nod, positive sign for CVS/Aetna

2018-09-17 reuters
(Reuters) - Health insurer Cigna Corp’s (CI.N) $52 billion acquisition of pharmacy benefits manager Express Scripts Holding Co has passed U.S. antitrust scrutiny, the companies said on Monday, allowing them to proceed with a combination they say will lead to lower costs by better coordinating pharmacy and medical benefits.
ATHTF BRK.A TWX ANTM CI CVS TWC HUM AET ANTX

20
Cigna-Express Scripts deal gets US antitrust approval

2018-09-17 channelnewsasia
Health insurer Cigna Corp's US$52 billion acquisition of pharmacy benefits manager Express Scripts Holding Co has passed U.S. antitrust scrutiny, the companies said on Monday, allowing them to proceed with a combination they say will lead to lower costs by better coordinating pharmacy and medical benefits.
ATHTF BRK.A TWX ANTM CI CVS TWC HUM AET ANTX

245
Stocks To Watch: Oracle Looks To Lift Tech Sector

2018-09-15 seekingalpha - 3
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
DOVA GIS TXN CAT AZO TWX RCL OPRF MAS HABT SHAK SUM BOX SONC RCII ABBV USCR FOX REGN BAC SQ DFS TRV COF-P WK BX JACK SYF AIG WEN ALL IDA KNSA NVS ABBV MSFT FL ZOES PFE ADS FOXA MLM JD NIO ATH DRI CX PYPL AXP MCO JBHT BRO EXP USB BAC COF-D COF-C COF-F HIG AAPL VMC TSG ORCL DEO MCD BMY RRGB WBC C CMCSA O THO MA M COF FDX NAVG HUM SNY RHT DSKE JPM IBOC MU DHR

16
Top Analyst Upgrades and Downgrades: American Superconductor, Galapagos, Humana, Intel, Philips, Pinduoduo, Qualcomm, Wayfair and More

2018-09-13 247wallst - 1
Stocks were indicated to open stronger on Thursday after a mixed index showing on Wednesday. The major U.S. equity indexes remain near all-time highs, while most international markets are not. One issue that stands out is that investors have seen less upside from buying on market pullbacks than in prior years. Investors also need to consider how they want to have their investments positioned for the rest of 2018.
AQST CARA CNCE DRNA HUM W ALDX AMSC CTMX TRI QCOM INTC FEDU

4
WellCare (WCG) Buys Meridian, Boosts Medicaid Membership

2018-09-05 zacks
WellCare Health Plans, Inc. (WCG - Free Report) recently announced completing its pending acquisition of Meridian Health Plan of Michigan, Inc., Meridian Health Plan of Illinois, Inc. and MeridianRx, together known as the Meridian. The transaction was effective Sep 1, 2018 and the deal was fixed at an approximate value of $2.5 billion. On closing the buyout, Meridian now becomes a subsidiary of WellCare.
UAM KND KDNUU WCG ANTM HUM UNH UAMCP

58
Top Analyst Upgrades and Downgrades: Amazon, Apple, BP, CSX, GE, Humana, Myriad Genetics, Mondelez UnitedHealth, Vodafone and More

2018-09-05 247wallst
Stocks were indicated lower on Wednesday morning. Even though the major market equity indexes may have recently hit all-time highs, investors have seen less upside when they have bought pullbacks. Investors also are trying to decide how they want their investments positioned for the rest of 2018.
ATHTF BIO.B DRI BP BIO AMZN AAPL MYGN CSX MS GE GEC ANTM HUM BP.A BP.B BP TRI GNE BPAQF ANTX

4
UnitedHealth's Optum to Jointly Acquire Sound Physicians

2018-09-04 zacks
UnitedHealth Group Incorporated’s (UNH - Free Report) health service business, branded as Optum, and private equity firm, Summit Partners, are together going to acquire a controlling interest in Tacoma-based Sound Physicians. Total value of this transaction is $2.2 billion. With this deal, the company would be able to expand its OptumHealth portfolio as well as continue its focus on care delivery, which has been really successful over the past few quarters through provider acquisitions.
CHTR KND KDNUU WCG ANTM HUM UNH

94
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q2 2018 Update

2018-09-03 seekingalpha - 1
Glenview Capital Management's 13F portfolio value decreased from $17.10B to $14.66B this quarter. The number of positions decreased from 52 to 49.
LOW ATHTF FLEX LBTY WBA ENL CVS HPE SHPG NWL LBTYK LILAB WMB DOW MTOR CAH DXC AET CMCSK IQV EBAY MIK TMUSP TMUS BKD CBS.WD VER CNDT GOOGL LILAK RLGY MSFT CPV MHK ENDP FB PAH TMO CCV MCK CCZ GOOG DLPH CHTR AGN DXC.WI CI ARMK HOLX CBS CSC CBS.A CMCSA FTI.WI FMC LBTYB LBTYA FDX ANTM HUM DWDP ABC V CCV.CL FDC THC APTV ANTX LILA

2
HUM / Humana, Inc. FORM 8-K (Current Report)

2018-08-31 sec.gov - 1
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
HUM

14
Workday's Business Model Strengths And Risks

2018-08-31 seekingalpha - 1
Despite competition from established companies such as Oracle and SAP, Workday's cloud-based applications have seen gains of 20%.
SAP JWN SFM WDAY HUM QCOM ORCL CRM

4
Humana (HUM) Launches Center for Digital Health Enhancement

2018-08-28 zacks
Humana Inc. (HUM - Free Report) operates as one of the best health and well-being companies in the United States. The company recently announced its series of strategic moves to boost capabilities in the field of technology, digital health and analytics. This in turn, will support the company’s integrated care delivery model and other programs. The company is launching Humana Studio H, a center for digital health and analytics, which would be located in Boston's Seaport District.
WCN REGN ANTM HUM UNH

4
Humana (HUM) Hits 52 Week High: Will the Rally Continue?

2018-08-27 zacks
Shares of Humana Inc. (HUM - Free Report) hit a 52-week high of $332.72 in Friday’s trading session before closing a tad lower at $331.44, primarily driven by the company’s strategic repositioning of its portfolio as well as its solid performance in the second quarter. The stock has surged nearly 30% in the past year, underperforming its industry’s growth of 34.9%.
KND HCCDZ HCHC KDNUU WCG ANTM HUM UNH

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to HUM / Humana, Inc. on message board site Silicon Investor.

Jokes and Humor Only Jokes and Humor Only Jokes and Humor Only Humble1 and Swing Trading Friends Humble1 and Swing Trading Friends Humble1 and Swing Trading Friends
Human Brain, The Human Brain, The Human Brain, The Political Humor- Left and Right! Political Humor- Left and Right! Political Humor- Left and Right!
HuMAB companies HuMAB companies HuMAB companies Humor Humor Humor
The SI Humidor The SI Humidor The SI Humidor Humanists, atheists, agnostics, and other freethinkers! Are Humanists, atheists, agnostics, and other freethinkers! Are Humanists, atheists, agnostics, and other freethinkers! Are
Human Genome Sciences, Inc. (HGSI) Human Genome Sciences, Inc. (HGSI) Human Genome Sciences, Inc. (HGSI) Complete Genomics GNOM DNA analysis for human genome Complete Genomics GNOM DNA analysis for human genome Complete Genomics GNOM DNA analysis for human genome
CUSIP: 444859102